In addition, the P/C ratio of CD44 expression showed much higher sensitivity and specificity for predicting invasiveness of GBM (100% and 83.3%, respectively) than CD44 expression in the tumor periphery (85.7% and 79.2%, respectively). This evidence concerns the gene CD44 and glioblastoma.